Drug analysis: Cotellic

  • ID: 4462191
  • Drug Pipelines
  • 26 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Cotellic (cobimetinib; Exelixis/Roche) is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), a serine/threonine kinase that is a component of the RAS/RAF/MEK/ERK pathway. Cotellic specifically binds to and inhibits the catalytic activity of MEK, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation. In preclinical studies, oral dosing of Cotellic resulted in potent and sustained inhibition of MEK in RAS or BRAF mutant tumor models. Cotellic is being developed by Roche under a collaboration agreement with Exelixis.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Cotellic: Colorectal cancer (CRC)
Cotellic: Melanoma

List of Figures
Figure 1: Cotellic for colorectal cancer - SWOT analysis
Figure 2: Drug assessment summary of Cotellic for colorectal cancer
Figure 3: Drug assessment summary of Cotellic for colorectal cancer
Figure 4: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
Figure 5: Cotellic in melanoma - SWOT analysis
Figure 6: Drug assessment summary of Cotellic for melanoma
Figure 7: Drug assessment summary of Cotellic for melanoma

List of Tables
Table 1: Cotellic drug profile
Table 2: Cotellic Phase III trial in colorectal cancer
Table 3: Cotellic early-phase data in colorectal cancer
Table 4: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
Table 5: Patients treated with Cotellic in the US and five major EU markets, by country, 2016-25
Table 6: Cotellic drug profile
Table 7: Cotellic pivotal trial data in melanoma
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll